Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Neutral

Analyst Rating

Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Gamida Cell Ltd. Ordinary Shares (GMDA)

Biological Products, (no Disgnostic Substances)

https://www.gamida-cell.com

Gamida Cell Ltd is a clinical-stage biopharmaceutical company that is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumors and blood cancers and other serious blood diseases. The company applies a proprietary expansion platform leveraging the properties of nicotinamide, or NAM, to allogeneic cell sources including umbilical cord blood-derived cells and natural killer, or NK, cells to create cell therapy candidates with the potential to redefine standards of care. Its primary product candidate is Omidubicel, an advanced cell therapy candidate for allogeneic hematopoietic stem cell transplant and GDA-201 is the company's lead investigational NK cell-based cancer immunotherapy product candidate.

5 NAHUM HAFZADI STREET
JERUSALEM, L3

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/26/2018

Market Cap

4,337,295

Shares Outstanding

132,639,999

Weighted SO

132,638,514

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

BLRX --.--%

ARDX --.--%

LXRX --.--%

MCRB --.--%

IBRX --.--%

PLX --.--%

IOVA --.--%

IMGN --.--%

Beta

1.0320

Last Div

0.0000

Range

0.03-2.51

Chg

-0.0073

Avg Vol

9377545

Mkt Cap

4337295

Exch

NASDAQ

Country

IL

Phone

972 2 659 5666

DCF Diff

0.0697

DCF

-0.0262

Div Yield

0.0000

P/S

1.6220

EV Multiple

-1.8477

P/FV

-0.2666

Div Yield %

0.0000

P/E

-0.2261

PEG

-0.0030

Payout

0.0000

Current Ratio

0.3522

Quick Ratio

0.2725

Cash Ratio

0.2616

DSO

140.1851

DIO

116.3031

Op Cycle

256.4882

DPO

321.4011

CCC

-64.9129

Gross Margin

-1.3074

Op Margin

-12.3848

Pretax Margin

-8.2610

Net Margin

-8.2610

Eff Tax Rate

0.0512

ROA

-0.2777

ROE

1.8796

ROCE

2.1870

NI/EBT

1.0000

EBT/EBIT

0.6670

EBIT/Rev

-12.3848

Debt Ratio

0.9815

D/E

-4.1690

LT Debt/Cap

-0.1095

Total Debt/Cap

1.3156

Int Coverage

23.9978

CF/Debt

-1.0122

Equity Multi

-4.2476

Rec Turnover

2.6037

Pay Turnover

1.1357

Inv Turnover

3.1384

FA Turnover

0.0622

Asset Turnover

0.0336

OCF/Share

-0.5176

FCF/Share

-0.5197

Cash/Share

0.1622

OCF/Sales

-29.5585

FCF/OCF

1.0042

CF Coverage

-1.0122

ST Coverage

-1.0368

CapEx Coverage

-238.5524

Div&CapEx Cov

-238.5524

P/BV

-0.2666

P/B

-0.2666

P/S

1.6220

P/E

-0.2261

P/FCF

-0.0546

P/OCF

-0.0632

P/CF

-0.0632

PEG

-0.0030

P/S

1.6220

EV Multiple

-1.8477

P/FV

-0.2666

DPS

0.0000

Latest Headlines (EST)

Benzinga Dec 05, 11:01 Expert Ratings for Gamida Cell GlobeNewswire Inc. Nov 27, 20:11 Gamida Cell to Host Virtual Thought Leader Fireside Chat on December 4, 2023 GlobeNewswire Inc. Nov 27, 20:11 Gamida Cell to Host Virtual Thought Leader Fireside Chat on December 4, 2023 GlobeNewswire Inc. Nov 27, 20:11 Gamida Cell to Host Virtual Thought Leader Fireside Chat on December 4, 2023 GlobeNewswire Inc. Nov 04, 08:00 Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire Inc. Nov 04, 08:00 Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Revenue Product Segmentation